Key Points Opus Genetics completed dosing in all 11 participants in Cohort 2 of its Phase 1/2 BIRD-1 trial. The cohort received OPGx-BEST1 at three…
November 04, 2026
NICE Expands Guidance for Rhythm Pharmaceuticals’ IMCIVREE to Include Adults With Bardet-Biedl Syndrome
Key Points NICE issued positive guidance extending IMCIVREE reimbursement eligibility to adults with genetically confirmed Bardet-Biedl syndrome, or BBS. The update enables eligible adults to…
Key Points EB-003 altered brain-wave activity in prefrontal and parietal cortical regions in mice, supporting functional activity in the central nervous system. Its profile differed…
Key Points Ardelyx has fully enrolled its Phase 3 ACCEL trial evaluating IBSRELA in adults with chronic idiopathic constipation, or CIC. The study compares twice-daily…
Key Points Allogene will deliver two invited presentations and a preclinical poster at the SITC Annual Meeting in Phoenix. Presentations will cover clinical experience from…
Key Points Rhythm will replace its low-to-mid-single-digit royalty structure with a 1% royalty on global net sales across its MC4R portfolio, including setmelanotide, bivamelagon and…
Key Points BrainsWay and Mindful Health Solutions are collaborating to expand access to noninvasive mental health treatments. The initiative includes BrainsWay Deep TMS and its…
November 02, 2026
Compass Pathways and DBSA Survey Highlights Burden of Treatment-Resistant Depression
Key Points A national survey included 261 people living with treatment-resistant depression and 73 caregivers. Some 95% of surveyed patients described themselves as functioning but…
November 02, 2026
Actuate Receives U.S. Patent Allowance for Elraglusib Oral Tablets Ahead of Planned Trial
Key Points The USPTO issued a Notice of Allowance for claims covering oral tablet compositions of elraglusib, Actuate’s investigational GSK-3β inhibitor. The allowance includes the…
Key Points Hims & Hers reported accelerating domestic revenue growth and international expansion, while raising its 2026 revenue outlook. Management reiterated 2030 targets of at…
Key Points Oral SKNY-1 significantly reduced body weight and fat mass compared with vehicle-treated controls in an exploratory mouse study. Weight reduction occurred without a…
Key Points Nuvation Bio plans to add SIGMA study sites in the United Kingdom, France, Sweden, Germany, Italy and Spain. The pivotal Phase 3 trial…